NewEdge Wealth’s TScan Therapeutics TCRX Stock Holding History

NewEdge Wealth’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$92.4K	Hold	91,463	–	–	﹤0.01%	1107
2025 Q4	$91.5K	Hold	91,463	–	–	﹤0.01%	1177
2025 Q3	$104K	Hold	91,463	–	–	﹤0.01%	1008
2025 Q2	$151K	Hold	91,463	–	–	﹤0.01%	942
2025 Q1	$126K	Hold	91,463	–	–	﹤0.01%	911
2024 Q4	$278K	Hold	91,463	–	–	﹤0.01%	784
2024 Q3	$455K	Hold	91,463	–	–	0.01%	640
2024 Q2	$535K	Hold	91,463	–	–	0.01%	533
2024 Q1	$791K	Hold	91,463	–	–	0.02%	462
2023 Q4	$533K	Hold	91,463	–	–	0.01%	500
2023 Q3	$234K	Hold	91,463	–	–	0.01%	584
2023 Q2	$229K	Hold	91,463	–	–	0.01%	582
2023 Q1	$192K	Hold	91,463	–	–	0.01%	585
2022 Q4	$142K	Buy	+91,463	New	+$224K	0.01%	523

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

NewEdge Wealth's TCRX Position: Q1 2026 in Review

NewEdge Wealth held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 91,463 shares worth $92.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

NewEdge Wealth first reported a position in TCRX in Q4 2022 and has held it in 14 quarters since. The position peaked at $791K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

NewEdge Wealth held 91,463 shares of TScan Therapeutics worth $92.4K as of Q1 2026.
NewEdge Wealth left its TScan Therapeutics share count unchanged in Q1 2026.
TScan Therapeutics made up ﹤0.01% of NewEdge Wealth's portfolio in Q1 2026, its #1107 holding.
NewEdge Wealth first reported a position in TScan Therapeutics in Q4 2022 and has held it in 14 quarters since.
NewEdge Wealth's TScan Therapeutics position peaked at $791K in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on NewEdge Wealth's 13F filing for Q1 2026, filed 13 May 2026.